Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 6:12 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 34 matching trials from the live ClinicalTrials.gov search.
Conditions
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Interventions
Pacritinib, Physician's Choice medications
Drug
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
18 Years and older
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 29 more
Completed Phase 2 Interventional Results available

Alii Supplement Study

NCT07271316
Conditions
Nutrient Deficiency, Happiness, Digestive Health, Vulnerability to Disease, Mood Swings, Energy
Interventions
Alii Supplement
Dietary Supplement
Lead sponsor
Texas Christian University
Other
Eligibility
18 Years to 25 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Fort Worth, Texas
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
Cabotegravir (CAB) tablet, Rilpivirine (RPV) tablet, Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine - Injectable Suspension (RPV LA), 2 NRTIs plus an INI, NNRTI, or PI
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
618 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 28 more
Completed Not applicable Interventional Accepts healthy volunteers

RCT of a Polyherbal Dietary Supplement for Prediabetes

NCT03388762
Conditions
Prediabetic State
Interventions
GlucoSupreme™ Herbal, Placebo
Dietary Supplement · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
4
States / cities
Baltimore, Maryland • Cincinnati, Ohio
Conditions
Non-Cystic Acne
Interventions
VitaMedica® Clear Skin Formula capsules, Placebo Capsules
Dietary Supplement · Other
Lead sponsor
Ablon Skin Institute Research Center
Other
Eligibility
18 Years to 40 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Manhattan Beach, California
Conditions
Rheumatoid Arthritis
Interventions
SKI-O-703 capsule, Placebo capsule
Drug
Lead sponsor
Oscotec Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Austin, Texas
Conditions
Arthritis, Rheumatoid
Interventions
SKI-O-703 capsule, Placebo capsule
Drug
Lead sponsor
Oscotec Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Austin, Texas
Conditions
Immune Thrombocytopenia
Interventions
SKI-O-703, Placebo oral tablet
Drug
Lead sponsor
Oscotec Inc.
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
4
States / cities
Los Angeles, California • Durham, North Carolina • Greenville, North Carolina + 1 more
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Effects of Dietary Conditions on Drug Response

NCT04315961
Conditions
Healthy
Interventions
Blinded drug dose conditions
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 45 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Terminated Phase 1 Interventional Accepts healthy volunteers

Effects of Dual Cyclooxygenase-2 and Carbonic Anhydrase Inhibition

NCT00780325
Conditions
Healthy Volunteers
Interventions
CG100649 (2 mg), Celecoxib, Placebo capsules, Naproxen, Acetazolamide, CG100649 (8 mg)
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Withdrawn Phase 1Phase 2 Interventional Accepts healthy volunteers

Prevention of Age-associated Cardiac and Vascular Dysfunction Using Avmacol ES

NCT05408559
Conditions
Diastolic Dysfunction, Systolic Dysfunction, Diastolic Heart Failure
Interventions
Sulforaphane
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
60 Years to 80 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Lubbock, Texas
Conditions
Drug Dependence
Interventions
Cycloserine, Diltiazem, Gabapentin, Isradipine, Naloxone, Nifedipine, Placebo, Saline, Verapamil
Drug · Device
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Little Rock, Arkansas
Conditions
Interstitial Cystitis, Chronic Interstitial Cystitis, Bladder Pain Syndrome
Interventions
Desert Harvest Aloe Vera Capsules, Placebo Capsules
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult Volunteers

NCT02478463
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
Cabotegravir tablet 30 mg once daily for 28 days., Cabotegravir injection 3 mL (200 mg/mL) IM given once on Day 1.
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
2
States / cities
Baltimore, Maryland • Pittsburgh, Pennsylvania
Completed Phase 3 Interventional Results available

Adaptive COVID-19 Treatment Trial 2 (ACTT-2)

NCT04401579
Conditions
COVID-19
Interventions
Placebo, Remdesivir, Baricitinib
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
1,033 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
53
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 44 more
Active, not recruiting Early Phase 1 Interventional

Modafinil and Cognitive Function in POTS

NCT01988883
Conditions
Postural Tachycardia Syndrome
Interventions
Placebo, Modafinil, Propranolol
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Candidemia, Mycoses, Fungal Infection, Fungemia, Invasive Candidiasis, Pneumocystis, Mold Infection, Invasive Fungal Disease, Prophylaxis of Invasive Fungal Infections, Aspergillus
Interventions
Rezafungin for Injection, Posaconazole, Fluconazole, Trimethoprim-sulfamethoxazole (TMP/SMX), Intravenous Placebo, Oral Placebo
Drug
Lead sponsor
Mundipharma Research Limited
Industry
Eligibility
18 Years and older
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • Stanford, California + 13 more
Conditions
Candidemia, Mycoses, Fungal Infection, Invasive Candidiases
Interventions
Rezafungin for Injection, Caspofungin, Fluconazole, intravenous placebo, oral placebo
Drug
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
19
States / cities
Birmingham, Alabama • Sacramento, California • Atlanta, Georgia + 16 more
Conditions
Medication Adherence, HIV
Interventions
dolutegravir oral tablet 50mg, emtricitabine/tenofovir alafenamide oral tablet 200mg/25mg, tenofovir disoproxil fumarate oral tablet 300mg, lamivudine oral tablet 300mg
Drug
Lead sponsor
Rhonda Brand
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Completed Not applicable Interventional Accepts healthy volunteers

Racial and Aging Effects of Acute Antioxidant Supplementation

NCT02157207
Conditions
Healthy
Interventions
Antioxidant, Placebo
Dietary Supplement · Other
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Infection, Human Immunodeficiency Virus
Interventions
744 Tablet, 744 LA Injection, Placebo Tablet, Placebo Injection
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
10
States / cities
San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 5 more
Conditions
Obesity and Overweight
Interventions
Postbiotic, Placebo
Dietary Supplement
Lead sponsor
ResBiotic Nutrition, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Completed Phase 3 Interventional Results available

Adaptive COVID-19 Treatment Trial 4 (ACTT-4)

NCT04640168
Conditions
COVID-19
Interventions
Baricitinib, Dexamethasone, Placebo, Remdesivir
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
1,010 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
61
States / cities
Birmingham, Alabama • Fresno, California • La Jolla, California + 50 more
Conditions
Health Adult Subjects
Interventions
Placebo (Microcrystalline Cellulose), Dihydroberberine(DHB)
Dietary Supplement
Lead sponsor
Nanjing Nutrabuilding Bio-tech Co., Ltd.
Other
Eligibility
35 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Addison, Illinois